BioVie Statistics
Total Valuation
BioVie has a market cap or net worth of $26.54 million. The enterprise value is $16.57 million.
| Market Cap | 26.54M |
| Enterprise Value | 16.57M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, after market close.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioVie has 54.92 million shares outstanding. The number of shares has increased by 22.46% in one year.
| Shares Outstanding | 54.92M |
| Shares Change (YoY) | +22.46% |
| Shares Change (QoQ) | +3.89% |
| Owned by Insiders (%) | 43.25% |
| Owned by Institutions (%) | 4.49% |
| Float | 22.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.54 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 1.37.
| Current Ratio | 1.47 |
| Quick Ratio | n/a |
| Debt / Equity | 1.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.77 |
Financial Efficiency
Return on equity (ROE) is -332.20% and return on invested capital (ROIC) is -250.16%.
| Return on Equity (ROE) | -332.20% |
| Return on Assets (ROA) | -137.90% |
| Return on Capital (ROIC) | -250.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.40M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.77% in the last 52 weeks. The beta is 1.21, so BioVie's price volatility has been higher than the market average.
| Beta (1Y) | 1.21 |
| 52-Week Price Change | -93.77% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 2.47 |
| Relative Strength Index (RSI) | 36.63 |
| Average Volume (30 Days) | 2,619,637 |
Short Selling Information
The latest short interest is 1.48 million, so 2.69% of the outstanding shares have been sold short.
| Short Interest | 1.48M |
| Short Previous Month | 1.54M |
| Short % of Shares Out | 2.69% |
| Short % of Float | 6.57% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -44.41M |
| Pretax Income | -43.27M |
| Net Income | -43.27M |
| EBITDA | -39.04M |
| EBIT | -39.25M |
| Earnings Per Share (EPS) | -$1.17 |
Balance Sheet
The company has $20.23 million in cash and $10.26 million in debt, giving a net cash position of $9.97 million or $0.18 per share.
| Cash & Cash Equivalents | 20.23M |
| Total Debt | 10.26M |
| Net Cash | 9.97M |
| Net Cash Per Share | $0.18 |
| Equity / Book Value | 7.49M |
| Book Value Per Share | 0.14 |
| Working Capital | 6.58M |
Cash Flow
| Operating Cash Flow | -41.11M |
| Capital Expenditures | n/a |
| Free Cash Flow | -41.11M |
| FCF Per Share | -$1.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioVie does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.46% |
| Shareholder Yield | -22.46% |
| Earnings Yield | -163.02% |
| FCF Yield | -154.90% |
Analyst Forecast
The average price target for BioVie is $8.00, which is 1,555.63% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 1,555.63% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 22, 2019. It was a reverse split with a ratio of 1:125.
| Last Split Date | Nov 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:125 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |